THROMBOLYTIC-ASSOCIATED CHOLESTEROL EMBOLI SYNDROME - CASE-REPORT ANDLITERATURE-REVIEW

Thrombolytics can cause cholesterol embolization syndrome (CES). This adverse effect has received less attention than other risks of thrombo lytic therapy, such as systemic bleeding and hemorrhage, with only spo radic reports of CES in the literature. Risk factors have not been con sistently identified and emphasized; therefore, occurrence of CES afte r thrombolysis remains difficult to predict, it results in substantial morbidity and mortality, and it lacks effective pharmacologic treatme nt. Heightened awareness of the disorder can aid in its correct identi fication and reporting.